Previous research has identified treatment attributes and outcomes for endometriosis patients, highlighting the need for tailored interventions to improve patient care. These studies emphasize the need to understand patient experiences, …
To evaluate patient satisfaction with the management of erratic bleeding during continuous hormone therapy for endometriosis using two different strategies: an active approach (tailored cycling), which involved discontinuation of the …
Endometriosis is a complex and multifaceted gynecological disorder characterized by the abnormal growth and presence of endometrial-like tissue outside the confines of the uterine cavity. It can lead to a …
Endometriosis is a chronic systemic disease characterized by the presence of endometrium-like glands and/or stroma outside the uterus, usually with an associated inflammatory process. It affects around 5-10% of women …
Endometriosis is a common gynecologic disorder with a significant burden of morbidity that is often subject to substantial diagnostic delay. While transvaginal ultrasound (TVUS) is the first-line imaging tool for …
Endometriosis (EMS) is a common chronic gynecological disorder affecting 5%-10% of reproductive-age women, often causing infertility, dyspareunia, pain, and limitations in physical and sexual activities. This condition is defined by …
Endometriosis is a chronic gynecological disorder associated with pain symptoms and infertility. The expression of microRNA miR-29c-3p is dysregulated in endometriosis. We aimed to identify novel molecular targets of miR-29c-3p …
Do the diagnostic delay and symptoms differ between endometriosis patients with advanced disease, defined as endometriosis involving the vagina, intestine, rectovaginal septum, or bladder (eVIRB), compared to patients without endometriosis …
Endometriosis affects up to 15% of women of reproductive age and can lead to various symptoms. More than 200 million people worldwide are at risk of higher than safe levels …
Endometriosis is currently considered a systemic inflammatory disease and different non-invasive inflammatory markers, such as cell-free DNA (cfDNA), have recently been evaluated. Hormonal treatments are frequently prescribed as first-line treatments …